Renal embolization with EVOH for adults on dialysis with ADPKD
Official title: RADIOLOGICAL AND CLINICAL EVALUATION OF RENAL EMBOLIZATION USING EVOH IN DIALYSIS PATIENTS WITH AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE: A PROSPECTIVE LONGITUDINAL OBSERVATIONAL STUDY
Run by Fondazione IRCCS Policlinico San Matteo di Pavia · NCT07535385 · Data updated 2026-11-12
This study tests whether blocking blood flow to very large polycystic kidneys with the liquid embolic EVOH can shrink kidney size and reduce symptoms in adults on dialysis with ADPKD.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Fondazione IRCCS Policlinico San Matteo di Pavia Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Pavia, Lombardy) |
| Status | Recruiting |
| Started | August 17, 2020 |
| Main results expected | August 17, 2026 |
| Study ends | August 17, 2026 |
| Registry record updated | April 17, 2026 |
| Trial ID | NCT07535385 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18–75 with ADPKD who are on dialysis, have a total kidney volume between 2000 and 5000 mL, have given informed consent, and are undergoing renal embolization are the intended participants.
✕Probably not a fit
People who cannot have MRI (incompatible implants, pacemakers, severe claustrophobia), those with kidney volumes outside the 2000–5000 mL range, or those not on dialysis are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective longitudinal observational study of adults with autosomal dominant polycystic kidney disease (ADPKD) who are on dialysis and undergo renal embolization using EVOH. Participants will have serial radiological follow-up, including MRI-based kidney volume measurements, alongside clinical monitoring for symptoms and complications. The study collects safety data and documents changes in renal volume and patient-reported outcomes over time without randomization or a control arm. Inclusion requires total kidney volume between 2000 and 5000 mL and the ability to undergo MRI.
Why it matters
Potential benefit: If successful, the procedure could meaningfully reduce kidney volume and related symptoms, improving comfort and quality of life for dialysis patients with very large polycystic kidneys.
How similar studies have gone: Previous renal artery embolization case series have reported size reduction and symptom relief, but use of EVOH in dialysis patients with ADPKD is relatively novel and less well documented.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * aged over 18 and under 75 * written informed consent * Patients with autosomal dominant polycystic kidney disease, with a kidney volume of between 2000 and 5000 mL, on dialysis, undergoing renal embolisation Exclusion Criteria: • Contraindications to MRI without contrast (ferromagnetic implants, incompatible pacemakers, surgical clips, severe claustrophobia or other conditions that may interfere with MRI)
Where it's running
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Lombardy, Italy Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VX-407 pharmacokinetics after a single dose in adults with ADPKD
This study tests how VX-407 is absorbed, distributed, metabolized, and excreted after a one-time oral dose in adults with polycystic kidney disease.
-
How VX-407 interacts with common birth control pills
This study tests whether VX-407 affects how birth control pills work in people with ADPKD.
-
Ren-Nu: a kidney-focused ketogenic diet program for people with polycystic kidney disease
This 16-week pilot will try a dietitian-led, kidney-safe ketogenic program plus KetoCitra in adults with ADPKD to improve metabolic health.
-
High blood pressure in children and teenagers at risk of ADPKD
This project will use MRI, blood tests, arterial stiffness measures, and ambulatory blood pressure monitoring to see how common high blood pressure is in 12–17-year-olds who have a parent with ADPKD.
-
Evaluating the safety of PYC-003 for treating a kidney disease
This study is testing a new drug called PYC-003 to see if it's safe for people with a specific type of kidney disease and healthy adults.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.